ImmunityBio, Inc. (IBRX) - Stock Analysis
Last updated: Apr 12, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
ImmunityBio posted ~700% YoY product-revenue growth, secured EU conditional approval and Saudi accelerated approval, and has multiple imminent clinical/label catalysts plus an investor update on 2026-03-03; the share price has climbed ~66% over 21 days and trades well above its 21âday SMA, positioning it as a highârisk but potent short-term momentum play.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Very high gross-margin ⢠Negative equity ⢠Financing reliance Despite very high gross margins and strong short-term liquidity, IBRX remains loss-making with large R&D-driven operating losses, negative equity and heavy long-term debt, persistent negative free cash flow, and clear reliance on external financing.
Price Behavior
Key Price Behavior Insights: ⢠Below short SMA ⢠Stabilizing base ⢠Elevated volatility Support Level: $6.66â$6.86 Resistance Level: $8.00â$9.40 Over the last month IBRX has traded below its ~$7.74 average after a sharp March rally to ~$9.40 and now sits at $7.28, implying a modest short-term bearish bias with support around $6.66â$6.86 and resistance near $8.00â$9.40 (break above ~$8.00 constructive; failure below $6.66 bearish).
Sentiment & News
Key News Insights: ⢠Rapid sales growth ⢠FDA warning ⢠Litigation surge ImmunityBio's Anktiva-driven sales and approvals sent shares soaring earlier in 2026, but an FDA warning over promotional claims and ensuing securities lawsuits triggered a sharp sell-off and sustained legal/regulatory risk.
AI Summary
ImmunityBio is no longer just a clinical-stage biotech but a high-volatility specialty-biologic whose value now hinges on whether ANKTIVA can sustain rapid revenue growth while management remedies FDA promotional concerns and contains litigation â not on clinical readouts alone. Investors should watch quarterly operating cash flow (need material improvement), resolution of the FDA warning without sales restrictions, and a credible deleveraging plan (or face meaningful dilution and valuation downside).
Description
ImmunityBio, Inc. is a clinical-stage biotechnology company developing therapies and vaccines targeting cancers and infectious diseases. The company applies multiple immunotherapy and cell therapy approachesâincluding engineered cytokine fusion proteins, synthetic immunomodulators, and both natural killer and T-cell platformsâand has candidates in Phase II/III trials for solid and liquid tumors (for example, bladder, pancreatic and lung cancers) as well as antiviral programs for pathogens such as SARS-CoV-2 and HIV. It maintains research collaborations and licensing arrangements with U.S. government institutes and several biopharma partners and is headquartered in San Diego, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Mar 2 | Mar 9 | IBRX | ImmunityBio, Inc. | ImmunityBio posted ~700% YoY product-revenue growth, secured EU conditional approval and Saudi accelerated approval, and has multiple imminent clinical/label catalysts plus an investor update on 2026-03-03; the share price has climbed ~66% over 21 days and trades well above its 21âday SMA, positioning it as a highârisk but potent short-term momentum play. | Closed | -19.1% |
| Feb 19 | Feb 26 | IBRX | ImmunityBio, Inc. | Multiple recent regulatory wins (EU conditional approval for ANKTIVA+BCG on 2026-02-18, Saudi approval, FDA Type B meeting) plus an EU commercialization deal and accelerating product revenue (~$38M quarter) have driven a >200% month-long rally; momentum remains strong into further catalyst and financing headlines despite high risk. | Closed | +10.9% |
| Jan 16 | Jan 23 | IBRX | ImmunityBio, Inc. | ImmunityBio is a hot idea driven by accelerating commercial revenue growth (700% annual increase in 2025), regulatory approvals expanding markets, positive clinical data mid-January 2026, nearly doubled stock price in past month, despite ongoing financial risks. | Closed | +16.9% |